Explore the vast range of titles available.

In this double-blind, placebo-controlled, 52-week trial among postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 μg of testosterone per day resulted in a significant although modest increase in the 4-week frequency of satisfying sexual episodes (1.4 more episodes per month), but the women were also subject to more adverse events, including androgenic side effects. In postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 '1;g of testosterone per day resulted in a significant although modest increase in the 4-week frequency of satisfying sexual episodes. The literature suggests that the prevalence of sexual problems among women ranges from 9 to 43%. 1 – 4 Among these women, hypoactive sexual desire disorder is a commonly reported, symptom-driven condition characterized by a decrease or absence of interest in sexual activity, causing distress. 5 Decreased libido is common after natural menopause 6 , 7 and bilateral oophorectomy. 8 – 10 Several studies have shown the efficacy and short-term safety of a transdermal patch delivering 300 μg of testosterone per day for the treatment of hypoactive sexual desire disorder in women who have undergone either surgically induced or natural menopause and who use concomitant estrogen. 11 – . . .

Aim. To develop a screening tool to allow a postmenopausal woman to determine whether to seek evaluation for hypoactive sexual desire disorder (HSDD). Methods. The Brief Profile of Female Sexual Function© (B-PFSF©) was developed using items from the Profile of Female Sexual Function© (PFSF©) and the Personal Distress Scale© (PDS©). Logistic regression analysis was used to select items best able to discriminate between women with HSDD (n = 743) and controls (n = 226) and a screening cut-off score was identified. Cross-validation analyses were conducted using PFSF and PDS responses from an independent group of 147 HSDD women and 104 controls. Forty cognitive interviews were additionally conducted to assess validity of the final tool. Results. A seven-item instrument was found to provide good discrimination between postmenopausal women with HSDD and controls and to be a reliable and valid tool. Ninety-six percent of women with HSDD and 97% of control women in the independent validation were classified correctly using the identified cut-off score. In the cognitive interviews, all women stated that the questionnaire was easy to complete and covered relevant aspects of sexual function. Conclusion. The Brief Profile of Female Sexual Function (B-PFSF) is psychometrically valid and appropriate for use as a self-administered screening tool.

The ROC curve is a commonly used summary measure of the accuracy of a diagnostic test. It is a plot of the true positive fraction, sensitivity, against the false positive fraction, one minus specificity, for increasingly stringent positivity criterion. Extensive methodology for estimating the ROC curve exists in the situation that patients who receive disease status verification represent a random sample of those who receive the diagnostic test. Bias can occur in the estimation of ROC curves if only some of the patients given the diagnostic test are selected for disease verification. If the probability of selection for verification depends on the diagnostic test result and/or covariates, then the verified sample is not a simple random sample. The bias that possibly arises from using only the verified subjects in the analysis is known as \"verification bias\". In this thesis, methods for deriving the maximum likelihood estimate for an ROC curve adjusted for variables affecting the likelihood of being verified, is given. Procedures which adjust for a verification mechanism which depends on the diagnostic test have been developed. Our methodology extends these procedures to adjust for \"verification bias\" when verification depends not only on the subject's diagnostic test result but also on additional covariates. Implementation of these methods are carried out using interactive software which we have developed. Our methods and software are illustrated on data from a two-phase study of dementia disorders; where selection for verification depends on the diagnostic test result, age and site.